The clinical effects of a new quinolone drug, pazufloxacin (PZFX), were investigated in obstetric and gynecologic infections.
1) The drug was administered to 19 patients with obstetric and gynecologic infections at a dose of 100-200mg 2-3 times a day for 2-14 days, and the efficacy was evaluated in 12 of them (5 patients with indefinite symptoms, 1 patient who didn't visit after treatment and 1 patient in whom medication was discontinued due to side effects were excluded).
2) The clinical efficacy was good in all patients: endometritis, 5 patients; salpingitis, 4; Bartholin abscess, 2; perineal abscess, 1.
3) Bacteriologically, all of the 8 strains of 8 species detected in 6 patients were eradicated.
4) As a side effect, mild rash was observed in 1 patient. No abnormal findings were observed on clinical laboratory tests. These findings indicate that PZFX is useful in obstetric and gynecologic infections.

View full abstract

We performed clinical studies on pazufloxacin (PZFX), a new oral quinolone antimicrobial agent, for its clinical efficacy in obstetric and gynecological infections. PZFX was administered to eight patients with endometritis, salpingitis, Bartholin's abscess, and vulva abscess.
The clinical efficacy was good in six cases, and poor in two cases. Bacteriologically, eight strains of five species were isolated from five patients, and all the strains were eradicated after the treatment.
Diarrhea was observed in one patient. No abnormal laboratory findings were observed.

View full abstract

A newly developed new quinolone antimicrobial drug, pazufloxacin (PZFX), was clinically investigated, and the following results were obtained.
1) PZFX was administered to one patient with endometritis and five with external genital infection, and the drug was effective in all six patients.
2) Seven strains of bacteria were isolated from the six patients, and all the strains were eradicated bacteriologically by the treatment. One case of Corynebacterium sp. was replaced.
3) No abnormal changes in clinical laboratory findings or side effects were observed in any of the patients.

View full abstract

Clinical studies were carried out in the field of obstetrics and gynecology to evaluate pazufloxacin (PZFX), a new oral quinolone.
PZFX was administrated to 13 patients with obstetric and gynecological infections. Clinical evaluation was possible in 11 patients (administration at a dose of 100-200 mg, 1-3 times a day for 7 to 9 days).
Clinical efficacy was evaluated as excellent in one patient and good in 10.
In terms of bacteriological efficacy, 13 of 14 strains were eradicated and one strain was persistent.
Nausea, dizziness and diarrhea were observed as side effects in one patient. Slight abnormal elevation of LDH was observed in one patient.

View full abstract

A newly developed oral quinolone antimicrobial drug, pazufloxacin (PZFX), was clinically studied in gynecologic patients.
The drug was administered at a dose of 200 mg (100mg for Bartholin's abscess) three times a day for seven days to 13 patients with gynecologic infections (six with endometritis, five with uterine adnexitis and two with a Bartholin's abscess), from whom informed consent was obtained. The drug was clinically effective in all the patients.
Bacteriologically, 16 of the 17 strains isolated before administration of the drug, which consisted of four strains of Gram-positive bacteria, seven strains of Gram-negative bacteria, five strains of anaerobic bacteria, and one strain of Chlamydia traehomatis, were eradicated, an eradication rate of 94.1%. The exception was one strain of Enterococcus faecalis.No abnormal changes in clinical laboratory test values or side effects were observed in any of the patients.
These results suggest that PZFX is useful for gynecologic infections.

View full abstract

We investigated the clinical effects of pazufloxacin (PZFX), a newly developed oral quinolone agent, in the gynecological infectious diseases.
PZFX was orally administered to 11 patients with Bartholin's abscess, pyosalpinx, salpingitis and cervicitis.
Among these cases, 8 were evaluated as effective, 3 as unknown.(The efficacy rate was 100%.)
Of the 3 cases, 1 case with cervicitis was excluded because of infection with Trichomonas. The 2 cases of salpingitis were excluded because of under unclar symptoms of infection.
PZFX was effective for gynecological infectious disease.
Bacteriologically 6 species, 10 strains were isolated from 7 patients.(The eradication rate was 90%.)
No side effects were observed during the treatment.

View full abstract

The clinical effects of pazufloxacin (PZFX), a newly developed, oral antibacterial agent of new quinolone line, on gynecological infections were examined.
The subjects of 12 patients with gynecological infections were classified into 3 cases with endometritis, 4 cases with salpingitis, 1 case with Bartholin's abscess, 1 case with bartholinitis, 1 case with mastitis, and 2 cases with vaginal stump's abscess. This drug at doses of 100 to 200 mg was p. o. administered two to three times a day. The period of administration ranged from 5 to 7 days.
The clinical effects were effective in all 10 cases except for 2 cases of unable assessment. Bacteriologically, 1 strain of Enterobacter aerogenes was isolated from 1 case, but hardly eliminated after administration of the drug, and Corynebacterium sp. appeared as replacing bacteria. Also, as adverse reactions attributable to this drug, stomach discomfort and diarrhea were observed in 1 case. No abnormal finding in laboratory test was observed.

View full abstract

Pazufloxacin (PZFX) was administered to 15 patients with gynecological infections.
The symptoms and signs of 14 patients except one chlamydial cervicitis improved.
Bacteriologically, bacteria were detected in 5 cases. The causative oraganisms were eliminated in 3 cases and replaced in 2 cases. Chlamydia trachomatis was not eliminated.
Neither subjective and objective side effects nor abnormal laboratory findings were observed.
PZFX is expected to be useful in the treatment of gynecologic infections.

View full abstract

We evaluated the clinical efficacy of pazufloxacin (PZFX) in 27 patients including 1 with acute otitis media, 13 with acute exacerbation of chronic otitis media, 2 with acute otitis externa, 1 with acute sinusitis, 1 with acute exacerbation of chronic sinusitis and 9 with acute tonsillitis. PZFX was orally administered postprandially at a dose of 100mg or 200mg three times a day for 2-14 days.
The clinical efficacy was evaluated as excellent in 10, good in 8, fair in 2, poor in 2 and non-evaluable in 5, an efficacy rate of 81.8%. Bacteriologically, 25 strains of 12 species were isolated from 19 patients. 20 of the strains were eradicated and 5 strains were unchanged.
Side effects consisted of mild diarrhea in one patinet, and in this one, we observed abnormalities in liver function tests and albuminuria.

View full abstract

The efficacy and safety of pazufloxacin (PZFX) were investigated in patients with otorhinolaryngological infectious diseases. The subjects were 19 patients consisting of 4 patients with acute otitis media, 7 with acute exacerbation of chronic otitis media, 3 with acute sinusitis, 2 with acute exacerbation of chronic sinusitis, 2 with acute tonsillitis and 1 with acute otitis externa.
PZFX was orally administered postprandially at a dose of 100mg or 200 mg three times a day for 3-15days. The clinical efficacy was evaluated as excellent in 5, good in 8, fair in 3 and non-evaluable in 3, an efficacy rate of 81.3%. Bacteriologically, 20 strains of 10 species were isolated from 14 patients, and 12 strains were eradicated and 8 strains were unchanged. The eradication rate was 60.0%.
There were no associated side effects or abnormal findings on clinical laboratory tests.
These results suggest that PZFX is an effective and highly safe drug for infectious diseases in otorhinolaryngology.

View full abstract

We clinically evaluated pazufloxacin (PZFX), a new quinolone-carboxylic acid derivatives, in the treatment of various otorhinolaryngological infections.
There were 42 subjects ranging in age from 17 to 79 years (mean age: 48.2 years) including 20 cases with otitis media, 8 with sinusitis, 8 with tonsillitis, 5 with otitis externa, 1 with right postoperative maxillary cyst with infection. PZFX was orally administrated in a dose of 100to 200mg, b.i.d. or t.i.d. for 1 to 14 days.
The clinical efficacy in 30 evaluable cases was excellent in 15 cases, good in 10, fair in 4, poor in 1. The clinical efficacy rate was 83.3%. Bacteriologically, 30 strains were isolated and 24 of them were eradicated. The eradication rate was 80.0%. No adverse reactions were observed except for one case of low-grade nausea and one case of middle-grade rash. No abnormal laboratory findings were observed except for slight elevation of eosinophils in one case but none of the abnormal fluctuations was serious or presented any particular clinical problems.
These results suggest that PZFX is considered to be a useful antimicrobial agent for treatment of many otorhinolaryngological infections.

View full abstract